Heart Centre, Department of Cardiology, University Hospital Bonn, Bonn, Germany.
PLoS One. 2020 Jul 22;15(7):e0236265. doi: 10.1371/journal.pone.0236265. eCollection 2020.
The preprocedural assessment of outcomes and patients' prognosis after interventional therapy of functional MR (FMR) is uncertain. Therefore, we aim to develop an easy-to-handle scoring system for adequate prediction of individual outcomes in patients with FMR after the interventional treatment.
We retrospectively used medical data of patients with symptomatic FMR, who underwent transcatheter mitral valve repair (TMVR) from January 2014 to August 2016 in our heart center. All patients had the mean follow-up of 18 months. All clinical and echocardiographic data originate from the "Bonner Mitral Valve Register Database".
We included 105 patients (76,7±8,8 years, 50,6% female) with symptomatic (NYHA functional class>II) moderate-to-severe or severe FMR at surgical high-risk. We modified the MIDA-Score for degenerative MR (DMR) according to the varying underlying pathomechanisms of FMR, called as "The modified MIDA Score". We found all-cause mortality of 7% within 18 months after the procedure. 34,1% of our cohort was rehospitalized; 90% of those were due to cardiovascular causes. The modified MIDA score was found to be a strong predictor for mortality and rehospitalization in patients with FMR (AUC: 0,89) and superior to the other conventional scoring systems in prediction of mortality (The modified MIDA-Score: AUC: 0,8, EuroSCORE II: AUC: 0,57, STS-Score: AUC: 0,51). The logistic regression analysis showed the modified MIDA score > 9 points to be the strongest predictor for mortality and rehospitalization after TMVR (OR: 3,35, p = 0,011).
The modified MIDA score was found to be a promising, easy-to-handle, elementary scoring system for adequate prediction of individual postinterventional prognosis in patients with FMR undergoing TMVR. Further evaluation and validation of this novel scoring system in prospective multicentric studies with a large number of patients is warranted.
功能性磁共振(FMR)介入治疗的预后和患者结局的术前评估尚不确定。因此,我们旨在开发一种易于操作的评分系统,以便在 FMR 患者接受介入治疗后对其进行个体化结局的充分预测。
我们回顾性地使用了 2014 年 1 月至 2016 年 8 月期间在我们心脏中心接受经导管二尖瓣修复术(TMVR)的有症状 FMR 患者的医疗数据。所有患者的平均随访时间为 18 个月。所有临床和超声心动图数据均来自“Bonner 二尖瓣瓣膜登记数据库”。
我们纳入了 105 名(76.7±8.8 岁,50.6%为女性)有症状(NYHA 心功能分级>II 级)、中重度或重度 FMR 且手术风险高的患者。我们根据 FMR 的不同潜在发病机制对退行性二尖瓣狭窄(DMR)的 MIDA 评分进行了修正,称为“改良 MIDA 评分”。我们发现术后 18 个月内全因死亡率为 7%。我们队列中有 34.1%的患者再次住院,其中 90%是心血管原因导致的。改良 MIDA 评分是 FMR 患者死亡和再住院的强有力预测因子(AUC:0.89),优于其他传统评分系统对死亡率的预测(改良 MIDA-Score:AUC:0.8,EuroSCORE II:AUC:0.57,STS-Score:AUC:0.51)。逻辑回归分析显示,TMVR 后改良 MIDA 评分>9 分是死亡和再住院的最强预测因子(OR:3.35,p = 0.011)。
改良 MIDA 评分是一种有前途的、易于操作的、基本的评分系统,可对接受 TMVR 的 FMR 患者的个体化介入后预后进行充分预测。需要进一步在具有大量患者的前瞻性多中心研究中评估和验证这种新的评分系统。